GenVec, Inc.
Public company
Traded as NASDAQ: GNVC
Industry Pharmaceuticals
Founded 1992 (1992)
Headquarters Gaithersburg, Maryland, U.S.
Key people
Douglas J. Swirsky, President and CEO
Products CGF166Clinical trial#Phase 1/2
Number of employees

GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company working to build a pipeline of therapeutics and vaccines based on its adenovector technology platform that can realize the promise of gene-based medicine. The company's lead product candidate for hearing loss and balance disorders, partnered with Novartis, is in a first-in-man gene delivery Phase 1/2 clinical trial in patients with severe to profound hearing loss. GenVec therapeutics and vaccines have been administered to over 3,000 clinical study subjects.


    This article is issued from Wikipedia - version of the 12/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.